Can immune cell recovery predict transplant success?
NCT ID NCT07782684
First seen Aug 24, 2026 · Last updated Aug 25, 2026 · Updated 1 time
Summary
This study follows 100 adults with blood disorders who receive an unrelated cord blood transplant. Researchers will measure levels of γδ T cells—a type of immune cell—in the blood at several time points over the first year. The goal is to see if the pattern of γδ T cell recovery is linked to key outcomes like overall survival and leukemia-free survival.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Umbilical cord blood transplantation
- What this could lead to
- If certain γδ T cell recovery patterns are linked to better outcomes, this could help doctors predict recovery and guide future transplant strategies.
- What could go wrong
- This is an observational study, so it cannot prove cause and effect. Results may not apply to all patients, and the clinical impact of γδ T cell levels remains uncertain.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 100 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Oct 2025
- Expected to finish
-
Oct 2030
An estimate. End dates often move.
- Lead sponsor
-
A government agency
The lead sponsor is a government body.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The study population will consist of patients undergoing their first allogeneic unrelated donor umbilical cord blood transplantation as standard treatment for their underlying hematological diseases (both malignant and non-malignant) in the Department of Hematology at the First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital).
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * 1: Patients undergo their first unrelated cord blood transplantation (UCBT) at our institution. 2: Diagnosis of a hematologic malignancy or disorder eligible for UCBT (e.g., acute leukemia, myelodysplastic syndrome, severe aplastic anemia) 3: Willing and able to provide written informed consent. 4: No restrictions on gender, age, or race. Exclusion Criteria: * Participation in an interventional clinical trial investigating prophylactic donor-derived cell infusion (e.g., DLI, MSC) during the study period.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Hematologic disease and disorders are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
the First Affiliated Hospital of University of Science and Technology of China
RECRUITINGHefei, Anhui, 230000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.